Daniel Wolfe, BARDA to Give Presentation at GTCbio's Antiviral Drugs R&D Conference

    SAN DIEGO, CA, March 25, 2016 /24-7PressRelease/ -- Daniel Wolfe, Health Scientist of the Division of CBRN Countermeasures at the Biomedical Advanced Research and Development Authority (BARDA), will give a presentation on "BARDA Response to the Ebola Epidemic in West Africa; Seeking to Meet Emergency Medical Countermeasure Needs" at GTCbio's 5th Antiviral Drugs Research & Development on June 1-2, 2016 in San Diego, CA.

The Ebola epidemic in West Africa proved to be the largest in the history of Filovirus outbreaks. The epidemic was declared a public health emergency of international concern, and to date, more than 28,000 cases have been identified with more than 11,000 deaths. In collaboration with other U.S. Government and international partners, the Biomedical Advanced Research and Development Authority (BARDA) initiated investments in vaccines and therapeutics, seeking to build medical countermeasure capabilities in the event of future outbreaks. The urgency associated with the epidemic led to multiple vaccine and therapeutic candidates being evaluated in clinical trials starting in late 2014. Lead vaccine candidates are now continuing to advance toward licensure for an indication against Ebola, and BARDA has a long term goal of developing countermeasures against other viral hemorrhagic fevers in the Filoviridae family as well. In support of its mission, BARDA has also developed an infrastructure which may be leveraged in the future to support product developers depending on their stage of maturity and technical needs.

Daniel Wolfe is developing a portfolio of advanced research and development focused on vaccines against Ebola and Anthrax. The Ebola epidemic in West Africa showed that there are still many unmet needs in terms of medical countermeasures against this pathogen. BARDA participated in the response to the epidemic by supporting the manufacturing of multiple vaccine candidates, and will continue to try to advance lead candidates towards licensure. Prior to joining BARDA, Daniel Wolfe worked at the Defense Threat Reduction Agency (DTRA) under the U.S. Department of Defense, developing a research program centered on earlier stage vaccine development for a wide range of pathogens.

The 5th Antiviral Drugs Research & Development Conference brings together a mix of academic and industry authoritative experts from leading affiliations (Harvard Medical School, The Scripps Research Institute, Arbutus, Sanofi Pasteur, U.S. Government Military HIV Research Program (MHRP), etc.) to cover many current and relevant aspects of new inhibitory mechanisms, longer acting drugs, and strategies en route for cures in HIV, RSV, Hepatitis B/C, Influenza, etc.

This conference is also part of our larger Infectious Diseases World Summit, which consists of 4 total conferences:

14th Vaccines Research & Development
13th Anti-Infectives Partnering & Deal-Making
5th Antiviral Drugs Research & Development
2nd Bugs & Drugs: Antibacterial Drug Discovery

For more information, please visit the website: http://www.gtcbio.com/antiviraldrugs

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
http://www.gtcbio.com/
Email: [email protected]
Phone: (626) 256-6405
Fax: (626) 466-4433

About GTCbio
GTCbio is a leading information center that provides quality forums, which facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. Our conferences cover a variety of topics, such as stem cell therapeutics, infectious diseases, biotech partnering, pharmaceutical litigation, government regulation, bio-based chemicals and many more. Founded in 2002, GTCbio stimulates scientific discussions, offers key business insights, and promotes partnering and deal-making in the ever-changing biotech and pharmaceutical world.

# # #